TABLE 5.
Indication and timing of concurrent thoracic radiotherapy and PCI in LS-SCLC
| Thoracic RT in SCLC | LS-SCLC (stage I–III: cT1–4, N0–3, M0) Bulky mediastinal disease Residual mediastinal disease after induction chemotherapy |
Concurrent starting with the first or second cycle of chemotherapy Could consider with third cycle of chemotherapy to achieve tumour response to initial chemotherapy to reduce radiation toxicity |
Twice daily thoracic RT of 45 Gy in 1.5 Gy per fraction over 3 weeks Alternative regimen, daily thoracic RT of 60–70 Gy in 1.8–2.0 Gy per fraction over 5 weeks |
| PCI in LS-SCLC | Recommended for stage II–III LS-SCLC without progressive disease, age <70 years with good performance status (ECOG 0–2) | After the completion of 4–6 cycles of chemotherapy and concurrent thoracic RT | 25 Gy in 10 fractions |